PUBLIC COMPANY
saveTaiho Oncology Inc
updated 5mo ago
community read0 votes
🐶 often sniffed alongside
top 5pipeline
5
marketed
2
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(5)
pipeline depth5 products
1Phase 11Phase 32Marketed1Unknown
Marketed
(tipiracil hydrochloride + trifluridine)
Adenocarcinoma Of The Gastroesophageal Junction
Marketedfutibatinib
Bile Duct Cancer (Cholangiocarcinoma)
Fibroblast growth factor receptor
Phase 3(azacitidine + cedazuridine)
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Phase 1TAS-2940
Solid Tumor
drugLYTGOBI
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earningsWhen Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.biospace · 6d ago
- BioSpace 2027 Best Places to Work shines light on most admired employersThe list honors 50 life sciences employers of choice. Employees at SERB Pharmaceuticals and CSL Behring share why their companies stand out.biospace · 9d ago
- ArriVent collapses on disappointing lung cancer dataMore than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.biopharma_dive · 1mo ago
- Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefitAnalysts believe Cullinan Therapeutics and Taiho Oncology can overcome the safety risks as zipalertinib “sets [a] new bar” for first-line treatment of a type of lung cancer. The candidate is alread…biospace · 2mo ago
- Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancerCullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…fiercebiotech · 2mo ago
- New Taiho, Cullinan data heats up lung cancer drug battleThe findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.biopharma_dive · 3mo ago
- Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competitionTaiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.biospace · 3mo ago
- Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contestTaiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…endpoints · 3mo ago
- FDA Approves Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AMLThe FDA has approved oral decitabine/cedazuridine plus venetoclax for newly diagnosed AML unfit for intensive chemo, based on phase 2 ASCERTAIN-V data.onclive · 6mo ago
Data sources
Found something off?
comments(0)
5-min edit window · permanent after that